Table 2 Hospitalized patients in the infectious diseases and ICU departments: a three-periods assessment comparison. Bef-F: December 7th to 21st 2020, Aft1-F: January 24th to February 7th, Aft2-F: February 8th to 22nd.

From: COVID-19 patients age, comorbidity profiles and clinical presentation related to the SARS-CoV-2 UK-variant spread in the Southeast of France

Infectious diseases patients

Bef-F n = 51

Aft1-F n = 72

Aft2-F n = 54

p

1st symptoms—admission—days (SD)

7.5 (4.5)

6.9 (3.3)

9.4 (5.6)**

0.01

Age—mean (SD)

70.7 (13.6)

66.9 (15.8)

59.2 (14.0)*,**

< 0.001

Sex ratio (male/female)

1.83

1.57

1.35

0.745

Diabetes—n (%)

17 (33%)

16 (22%)

12 (22%)

0.306

Hypertension—n (%)

20 (39%)

30 (42%)

15 (28%)

0.252

Obesity—n (%)

10 (20%)

18 (25%)

9 (17%)

0.503

Immunosuppression—n (%)

4 (8%)

5 (7%)

1 (2%)

0.341

No comorbidity—n (%)

8 (16%)

18 (25%)

23 (42%)*,**

0.007

Charlson Index (CCI)—mean (SD)

1.3 (1.6)

0.9 (1.0)

0.6 (0.8)*,**

0.04

Clinical and radiological data

Respiratory rate/min—mean (SD)

25.0 (6.1)

26.9 (5.8)

24.9 ± (5.9)

0.051

Room air SpO2%—mean (SD)

90.5 (7.2)

91.2 (5.6)

92.1 (4.6)

0.335

CRP mg/L—mean (SD)

94.3 (85.9)

108.8 (77.7)

94.4 (68.2)

0.316

CT-scan opacitiesa over 50% (n, %)

8 (16%)

10 (14%)

9 (17%)

0.951

ICU admission

12 (23%)

19 (26%)

19 (35%)

0.374

ICU patients

Bef-F n = 13

Aft1-F n = 20

Aft2-F n = 22

p

Age (years)—mean (SD)

68.4 (10.8)

64.5 (10.7)

60.6 (12.5)

0.154

Male—n (%)

9 (69%)

13 (65%)

16 (72%)

0.863

Mechanical ventilation—n (%)

7 (54%)

5 (25%)

10 (45%)

0.203

HFNC—n (%)

5 (38%)

14 (70%)

9 (45%)

0.140

SAPSII—mean (SD)

40.6 (18.1)

35.5 (15.3)

40.0 (19.9)

0.566

Worst P/F—mean (SD)

92 (33)

112 (62)

87 (24)

0.244

  1. Comparison between groups by a non-parametric one-way ANOVA on ranks (Kruskal–Wallis test). Post hoc analysis (Fischer exact-test or Mann–Whitney U-test, if required): *p < 0.05 versus December **p < 0.05 versus January.
  2. aTypical Covid-19 related imaging such as subpleural ground-glass opacities and subsequent consolidations, small vessel or intralobular septum thickening (33,631,941).
Back to article page